Arvinas reported revenues of $30.3 million and a net loss of $66.2 million for the third quarter of 2022. The company is on track to initiate enrollment of two Phase 3 trials with ARV-471 in patients with first- and second-line metastatic breast cancer.
Initiated activity to enroll four new clinical trials with ARV-471.
Began a Phase 2 trial with ARV-766.
Strengthened executive team and Board of Directors.
Expect the initiation of two Phase 3 trials with ARV-471 in patients with metastatic breast cancer by the end of this year, and a Phase 3 trial with bavdegalutamide in men with metastatic castrate resistant prostate cancer in the second half of 2023.
Arvinas believes its cash, cash equivalents, restricted cash and marketable securities as of September 30, 2022 is sufficient to fund planned operating expenses and capital expenditure requirements multiple years beyond 2024.
Analyze how earnings announcements historically affect stock price performance